IRADIMED CORPORATION (IRMD)
IRADIMED CORPORATION (IRMD) is a healthcare company (medical devices) based in the United States. The share price is $83.45, down 1.64% on the day, which values the company at $1.07B. Price as of 18 Nov 2026, 12:48 UTC, from Yahoo Finance.
Key facts
- Share price
- $83.45−1.64% today
- Market value
- $1.07B
- P/E ratio
- 44.6×last 12 months
- Forward P/E
- 34.2×
- Dividend yield
- 0.94%
- Funk Score
- 77/100
- Against its own history
- Well above its usual priceusual price $61.95
- 200-week average
- $61.4036% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
IRADIMED CORPORATION in more detail
IRMD trades at 44.6× its last twelve months' earnings, 34.2× next year's expected earnings, 11.9× sales. Measured against its own history, the price is 35% above what its usual multiples would imply ($61.95) — well above its usual price. It sits 36% above its 200-week average of $61.40.
Over the last five fiscal years IRADIMED CORPORATION has compounded revenue 21.5% a year, earnings per share 73.9% a year, free cash flow 25.2% a year. Its Funk Score is 77 out of 100 (financial strength 8.1, profitability 9.7, growth 9.7, value 3.2, each out of 10).
In its favour: Altman Z in the safe zone; Five straight years of revenue growth. Worth checking: Share count keeps rising.
IRADIMED CORPORATION (IRMD): questions and answers
What is IRMD's P/E ratio?
IRADIMED CORPORATION trades at 44.6× its last twelve months' earnings and 34.2× next year's expected earnings. At its fiscal year-ends over the past 12 years the P/E ranged from 18.5× to 378.7×, with a median of 46.9×.
What is IRADIMED CORPORATION's market cap?
IRADIMED CORPORATION is valued at $1.07B at a share price of $83.45.
Is IRMD overvalued or undervalued?
Against its own history, IRMD is well above its usual price: the price is 35% above the $61.95 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is IRMD above its 200-week moving average?
Yes. IRMD is 35.9% above its 200-week average of $61.40. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is IRADIMED CORPORATION growing?
Over the last five fiscal years IRADIMED CORPORATION's revenue grew 21.5% a year and its earnings per share 73.9% a year; over ten years revenue grew 10.2% a year.
Does IRMD pay a dividend?
Yes. IRADIMED CORPORATION's dividend yield is 0.94%, or $0.80 a share a year, paying out 41% of earnings.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “IRADIMED CORPORATION (IRMD) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/IRMD
Underlying data: Yahoo Finance; company filings with the SEC.